Merrimack initiates Phase 2 trial of MM-121 with erlotinib
MM-121 is a fully human monoclonal antibody that targets ErbB3, while erlotinib (Tarceva) is a small molecule directed at the epidermal growth factor receptor (EGFR). The study is
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.
Maintenance therapy using azathioprine or mycophenolate mofetil, helps consolidate remission and prevent relapse after the initial control of lupus nephritis. The 36-month, randomized, double-blind, double-dummy, phase 3 study